First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset*
Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Katsuyuki Hotta(Okayama University Hospital), Kazuma Kishi(Toho University), Shigeki Umemura(National Cancer Center Hospital East), Nobuyuki Yamamoto(Wakayama Medical University), Hiroshi Sakai(Hiroshima University), Atsushi Horiike(The Cancer Institute Hospital), Kaname Nosaki(National Cancer Center Hospital East), Akimasa Sekine(Kanagawa Cardiovascular and Respiratory Center), Takayasu Kurata(Kansai Medical University), Shinji Atagi(National Institute of Technology, Nara College), Kazuo Noguchi(MSD K.K. (Japan)), Hidehito Horinouchi(Tokyo National Hospital), Isamu Okamoto(Kyushu University Hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Shi Rong Han(Health Insurance Review and Assessment Service), Shunichi Sugawara(Sendai Kousei Hospital), Toyoaki Hida(Saitama International Medical Center), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Hideo Saka(Nagoya Medical Center), Nobuyuki Katakami(Takarazuka City Hospital), Hiroaki Okamoto(Yokohama Municipal Citizen's Hospital), Tatsuo Ohira(Tokyo Medical University), Victoria Ebiana(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keisuke Aoe(National Sanyo Hospital), Toshiaki Takahashi(Okayama University)
Cited by 18
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k